Geneva Pharmaceuticals Patent Pool (MPP) announced on its official website on March 17 that 35 companies have signed agreements with it to produce generic Pfizer’s new crown oral drug “Nematavir/Ritona” One of the ingredients of Paxlovid is nirmatrelvir.
Among the 35 companies, 5 Chinese pharmaceutical companies are: Huahai Pharmaceutical, Puluo Pharmaceutical, Fosun Pharmaceutical, Jiuzhou Pharmaceutical, In Shanghai Desano, Jiuzhou Pharmaceutical can only produce APIs, while the other 4 pharmaceutical companies can produce APIs and finished drugs at the same time.
Image source: MPP official website
These 35 companies produce medicines that can be sold to 95 low- and middle-income countries (excluding China), at a time when WHO has identified the spread of COVID-19 as an emergency of international concern. During the pandemic, Pfizer will not collect royalties on the drug from these companies.
But after the COVID-19 pandemic period ends, Pfizer will continue to exempt drug sales from low-income countries and will charge 5% for drug sales in low- and upper-middle-income countries % royalties, and 10% on sales to the private sector.
The agreement will expand access to Pfizer’s oral Covid-19 medicines in 95 low- and middle-income countries, representing approximately 53% of the world’s population.
Planning: Earth Cat, z_popeye
Producer: gyouza
Information source: MPP official website